Orocidin Achieves Milestone with QR-01 Safety Study
Orocidin A/S, a subsidiary of Nordicus Partners Corporation (OTCQB: NORD), is thrilled to announce the successful completion of its first toxicity study for QR-01, a groundbreaking treatment intended for aggressive periodontitis. This study is a significant stride towards establishing a new standard in periodontal treatments.
Understanding the Toxicity Study
During this preclinical study, Orocidin administered QR-01 to hamsters over a two-week span, utilizing doses that were significantly higher—5 to 8 times—than those planned for the upcoming efficacy study in humans. This rigorous approach was taken to ensure comprehensive safety profiling of the drug.
Results and Observations
In a positive outcome for the research team, all test subjects demonstrated remarkable tolerance to the drug. CEO and Founder of Orocidin, Allan Wehnert, expressed his satisfaction, highlighting that there were no adverse reactions or irritation noted at the drug application sites. The necroscopic examination post-study revealed no tissue changes, reinforcing the product's safety.
Looking Ahead: New Chapters for Orocidin
The successful outcome of this initial toxicity study marks a pivotal moment for Orocidin as it sets the stage for a more extensive eight-week toxicity study. This upcoming trial will delve deeper into the safety and efficacy of QR-01, potentially changing how aggressive periodontitis is treated.
Continued Commitment to Innovative Therapies
Orocidin is dedicated to developing innovative solutions in treating the dental disease landscape, particularly aggressive periodontitis. QR-01 stands out due to its dual-action capabilities, tackling both inflammation and bacterial infections concurrently. Such advancements could radically transform patient treatment options.
About Orocidin and Nordicus Partners Corporation
Orocidin operates under a clear mission: to create the leading therapy for aggressive periodontitis. Meanwhile, Nordicus Partners is recognized as a formidable U.S. publicly traded business accelerator focused on Nordic life sciences companies. Their expertise spans corporate finance activities, assisting businesses in navigating growth strategies, market development, and more. In a significant move, Nordicus acquired Orocidin A/S, aiming to bolster the portfolio of innovative healthcare solutions.
Contact Information
For more information, reach out to:
Mr. Henrik Rouf
Chief Executive Officer
Email: hr@nordicuspartners.com
Phone: +1 310 666 0750
Investor Relations Contacts:
Jonathan Paterson
Harbor Access Investor Relations
Email: Jonathan.Paterson@Harbor-Access.com
Phone: +1 475 477 9401
Frequently Asked Questions
What is QR-01?
QR-01 is a new treatment developed by Orocidin for aggressive periodontitis, focusing on both inflammation and bacterial infections.
How was the safety of QR-01 tested?
The safety was evaluated through a preclinical toxicity study where hamsters were dosed at higher concentrations than those intended for humans.
What were the results of the toxicity study?
All animals exhibited high tolerance with no significant adverse reactions, indicating a promising safety profile for QR-01.
What are the next steps for Orocidin?
The company plans to conduct an eight-week pivotal toxicity study to further evaluate QR-01's safety and efficacy.
Who is the parent company of Orocidin?
Orocidin is a subsidiary of Nordicus Partners Corporation, a company focused on supporting Nordic life sciences in the U.S.
